A Phase II Trial of Weekly Paclitaxel Plus Oral Estramustine in Patients With Hormone Refractory Prostate Cancer
OBJECTIVES: I. Determine the response rate (PSA and/or objective response) and duration of
response to weekly paclitaxel plus estramustine in patients with metastatic hormone
refractory prostate cancer. II. Determine the effect on quality of life of this regimen in
OUTLINE: Patients receive paclitaxel IV over 1 hour weekly for 4 weeks. Patients receive
oral estramustine the day before, the day of, and the day after paclitaxel administration
each week. Courses repeat every 4 weeks in the absence of unacceptable toxicity and disease
progression. A quality of life questionnaire is completed before treatment and 2 months
after treatment initiation.
PROJECTED ACCRUAL: A total of 17 patients will be accrued for this study.
Primary Purpose: Treatment
Stuart P. Leitner, MD
St. Barnabas Medical Center
United States: Federal Government
|St. Barnabas Medical Center||Livingston, New Jersey 07039|
|Monmouth Medical Center||Long Branch, New Jersey 07740-6395|